News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca PLC’s U.S. Sales Tumble As Generics Bite
October 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- AstraZeneca Plc, the U.K.’s second- biggest drugmaker, fell the most in almost nine months in London trading after saying fourth-quarter comparisons would be “demanding” as generic competition cuts into profit.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
AstraZeneca Pharmaceuticals LP
MORE ON THIS TOPIC
HIV
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
January 14, 2026
·
3 min read
·
Dan Samorodnitsky
Business
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals
January 14, 2026
·
4 min read
·
Tristan Manalac
Business
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches
January 14, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Lyra Shutters, EMD Serono Downsizes
January 14, 2026
·
44 min read
·
BioSpace Editorial Staff